| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于治疗心脏疾病的经取代的脲衍生物 | CN200580028071.1 | 2005-06-16 | CN101035525A | 2007-09-12 | 布拉德利·P.·摩根; 亚历克斯·穆奇; 卢普平; 埃丽卡·克里耐克; 托德·杼元; 戴维·摩根斯 |
| 特定经取代的脲衍生物例如通过增强心肌球蛋白来选择性地调节心肌原纤维节，可用于治疗包括充血性心力衰竭的收缩性心力衰竭。 | ||||||
| 2 | 无类固醇疾病管理 | CN201480081422.4 | 2014-07-31 | CN107072986A | 2017-08-18 | 罗杰·埃斯特贝里·史密斯; 尼古拉斯·詹姆斯·莱平; 桑迪普·古普塔 |
| 本发明涉及化合物1‑（2‑（4‑氟苯基）噻唑‑5‑基）‑1‑（吡啶‑4‑基）乙醇（“ASN001”）不配伍使用类固醇和/或以外消旋混合物的形式在疾病治疗，例如前列腺癌治疗中的应用。本发明还涉及在食物无关的方法中该化合物的使用。 | ||||||
| 3 | Compounds, compositions and methods | US15480618 | 2017-04-06 | US10035770B2 | 2018-07-31 | Bradley Paul Morgan; Alex Muci; Pu-Ping Lu; Erica Anne Kraynack; Todd Tochimoto; David J. Morgans, Jr. |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 4 | Compounds, compositions and methods | US14837201 | 2015-08-27 | US09643925B2 | 2017-05-09 | Bradley Paul Morgan; Alex Muci; Pu-Ping Lu; Erica Anne Kraynack; Todd Tochimoto; David J. Morgans, Jr. |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 5 | Ureas and their use in the treatment of heart failure | US13946353 | 2013-07-19 | US08871769B2 | 2014-10-28 | Bradley Paul Morgan; Alex Muci; Pu-Ping Lu; Erica Anne Kraynack; Todd Tochimoto; David J. Morgans |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 6 | Compounds, Compositions and Methods | US11630062 | 2005-06-16 | US20090036447A1 | 2009-02-05 | Bradley Paul Morgan; Alex Muci; Pu-Ping Lu; Erica Anne Kraynack; Todd Tochimoto; David J. Morgans, JR. |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 7 | Substituted urea derivatives for the treatment of heart disease | JP2007516674 | 2005-06-16 | JP2008503467A | 2008-02-07 | クレイナック，エリカ; トチモト，トッド; ムーシー，アレックス; モルガン，ブラッドリー，ピー; モルガンズ，デヴィッド; ルー，プー−ピン |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 8 | ステロイドフリー疾患管理 | JP2017526034 | 2014-07-31 | JP2017523242A | 2017-08-17 | アストバリー スミス ロジャー; ジェイムズ ラピング ニコラス; グプタ サンディープ |
| 本発明は、ステロイドを併用することなく、及び/又はラセミ体混合物の形態の、化合物1−(2−(4−フルオロフェニル)チアゾール−5−イル)−1−(ピリジン−4−イル)エタノール(「ASN001」)の使用に関する。それはまた、食事に無関係な方法におけるその使用に関する。 | ||||||
| 9 | Substituted urea derivative for treating heart failure | JP2011266808 | 2011-12-06 | JP2012097093A | 2012-05-24 | MORGAN BRADLEY P; MUCI ALEX; LU PU-PING; KRAYNACK ERICA; TOCHIMOTO TODD; MORGANS DAVID |
| PROBLEM TO BE SOLVED: To provide a therapeutic drug for systolic heart failure including congestive heart failure by selectively modulating cardiac sarcomere by potentiating cardiac myosin.SOLUTION: At least one chemical substance is selected from compounds (1) expressed by formula and pharmaceutically acceptable salts, chelates, non-covalent complexes, prodrugs and mixtures thereof. In the formula, W, X, Y and Z are independently -C= or -N=, provided that no more than two of W, X, Y and Z are -N=; n is 1, 2 or 3; Ris substituted amino, substituted heterocycloalkyl or the like; Ris substituted aryl, substituted aralkyl or the like; R, R, Rand Reach are hydrogen, halo, cyano, substituted alkyl or the like. | ||||||
| 10 | Compounds, compositions and methods | EP14180082.1 | 2005-06-16 | EP2862859A3 | 2015-05-06 | Morgan, Bradley P.; Muci, Alex; Lu, Pu-Ping; Kraynack, Erica; Tochimoto, Todd; Morgans, David |
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. |
||||||
| 11 | VERBINDUNGEN FÜR DIE DIAGNOSTIK NEURODEGENERATIVER ERKRANKUNGEN AM RIECHEPITHEL | EP11804933.7 | 2011-09-20 | EP2619591A2 | 2013-07-31 | SCHMIDT, Boris; KIESER, Daniel; BOLÄNDER, Alexander; HERMS, Jochen; HEYNY-VON HAUSSEN, Roland, Hans; GU, Jiamin |
| Subject of the present invention are compounds with high affinity for the Abeta protein, alpha-synuclein or for Tau-PHF aggregates, which are suitable as preferably fluorescent probes for the in vivo diagnosis of neurodegenerative disorders like e.g. Alzheimer's disease and Parkinson's disease. The compounds are characterized by suitable physicochemical properties (excitation wavelength, emission wavelength, Stokes shift, extinction) as well as a high affinity and selectivity for the target proteins. | ||||||
| 12 | COMPOUNDS, COMPOSITIONS AND METHODS | US16021418 | 2018-06-28 | US20180305316A1 | 2018-10-25 | Bradley Paul Morgan; Alex Muci; Pu-Ping Lu; Erica Anne Kraynack; Todd Tochimoto; David J. Morgans, JR. |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 13 | STEROID-FREE DISEASE MANAGEMENT | US15329465 | 2014-07-31 | US20170319563A1 | 2017-11-09 | Roger Astbury Smith; Nicholas James Laping; Sandeep Gupta |
| The present invention relates to the use of the compound 1-(2-(4-fluorophenyl)thiazol-5-yl)-1-(pyridin-4-yl)ethanol (“ASNOO1”) in treatments without concomitant use of a steroid and/or in the form of a racemic mixture, e.g. in prostate cancer treatment. It also relates to its use in methods that are food indifferent. | ||||||
| 14 | COMPOUNDS, COMPOSITIONS AND METHODS | US15480618 | 2017-04-06 | US20170267638A1 | 2017-09-21 | Bradley Paul Morgan; Alex Muci; Pu-Ping Lu; Erica Anne Kraynack; Todd Tochimoto; David J. Morgans, JR. |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 15 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | US15373832 | 2016-12-09 | US20170190672A1 | 2017-07-06 | Neelakandha S. Mani; Brett D. Allison; Zachary S. Sales; Jimmy T. Liang; Xiaohu Deng; Liansheng Li; Yun Oliver Long; Yuan Liu; Pingda Ren |
| Methods for preparing compounds having the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b and R4c, are as defined herein are provided. Related compounds and methods for making the same are also provided. | ||||||
| 16 | COMPOUNDS, COMPOSITIONS AND METHODS | US14837201 | 2015-08-27 | US20160115133A1 | 2016-04-28 | Bradley Paul Morgan; Alex Muci; Pu-Ping Lu; Erica Anne Kraynack; Todd Tochimoto; David J. Morgans, JR. |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 17 | COMPOUNDS, COMPOSITIONS AND METHODS | US14489705 | 2014-09-18 | US20150005296A1 | 2015-01-01 | Bradley Paul Morgan; Alex Muci; Pu-Ping Lu; Erica Anne Kraynack; Todd Tochimoto; David J. Morgans, JR. |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 18 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | US13946353 | 2013-07-19 | US20140038983A1 | 2014-02-06 | Bradley Paul MORGAN; Alex MUCI; Pu-Ping LU; Erica Anne KRAYNACK; Todd TOCHIMOTO; David J. MORGANS |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 19 | Disubstituted ureas and uses thereof in treating heart failure | US12238313 | 2008-09-25 | US08101617B2 | 2012-01-24 | Bradley Paul Morgan; Alex Muci; Pu-Ping Lu; Erica Anne Kraynack; Todd Tochimoto; David J. Morgans, Jr. |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
| 20 | Substituted urea derivatives for the treatment of heart disease | JP2007516674 | 2005-06-16 | JP5080970B2 | 2012-11-21 | モルガン，ブラッドリー，ピー; ムーシー，アレックス; ルー，プー−ピン; クレイナック，エリカ; トチモト，トッド; モルガンズ，デヴィッド |
| Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | ||||||
QQ群二维码
意见反馈
意见反馈